Analysts Anticipate GALAPAGOS NV/S (GLPG) Will Post Earnings of -$1.15 Per Share

Share on StockTwits

Wall Street analysts forecast that GALAPAGOS NV/S (NASDAQ:GLPG) will announce earnings of ($1.15) per share for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for GALAPAGOS NV/S’s earnings. The highest EPS estimate is ($0.30) and the lowest is ($1.66). GALAPAGOS NV/S reported earnings per share of ($0.50) during the same quarter last year, which would suggest a negative year over year growth rate of 130%. The firm is scheduled to report its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that GALAPAGOS NV/S will report full-year earnings of ($4.77) per share for the current year, with EPS estimates ranging from ($6.40) to ($3.91). For the next financial year, analysts forecast that the firm will post earnings of ($5.30) per share, with EPS estimates ranging from ($8.06) to ($3.77). Zacks’ EPS averages are an average based on a survey of analysts that cover GALAPAGOS NV/S.

A number of analysts have commented on the stock. BidaskClub raised shares of GALAPAGOS NV/S from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Morgan Stanley upped their price target on shares of GALAPAGOS NV/S from $138.00 to $139.00 and gave the company an “overweight” rating in a research report on Monday, April 29th. HC Wainwright upped their price target on shares of GALAPAGOS NV/S to $150.00 and gave the company a “positive” rating in a research report on Friday, March 29th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $130.00 price target on shares of GALAPAGOS NV/S in a research report on Thursday, May 2nd. Finally, Cowen reaffirmed a “buy” rating on shares of GALAPAGOS NV/S in a research report on Friday, February 22nd. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $127.27.

Shares of GALAPAGOS NV/S stock traded up $1.03 during trading on Wednesday, hitting $114.47. The company’s stock had a trading volume of 6,698 shares, compared to its average volume of 110,160. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.02. GALAPAGOS NV/S has a 52 week low of $85.00 and a 52 week high of $125.48. The stock has a market cap of $5.71 billion, a price-to-earnings ratio of -173.52 and a beta of 1.63.

Several hedge funds have recently added to or reduced their stakes in the company. Federated Investors Inc. PA boosted its position in shares of GALAPAGOS NV/S by 17.8% during the 3rd quarter. Federated Investors Inc. PA now owns 1,677,922 shares of the biotechnology company’s stock worth $188,648,000 after purchasing an additional 253,159 shares in the last quarter. BlackRock Inc. increased its stake in GALAPAGOS NV/S by 18.4% in the 3rd quarter. BlackRock Inc. now owns 365,413 shares of the biotechnology company’s stock valued at $41,083,000 after buying an additional 56,848 shares during the last quarter. Bank of New York Mellon Corp increased its stake in GALAPAGOS NV/S by 530.8% in the 4th quarter. Bank of New York Mellon Corp now owns 249,137 shares of the biotechnology company’s stock valued at $22,857,000 after buying an additional 209,642 shares during the last quarter. Alps Advisors Inc. increased its stake in GALAPAGOS NV/S by 14.5% in the 1st quarter. Alps Advisors Inc. now owns 87,116 shares of the biotechnology company’s stock valued at $10,261,000 after buying an additional 11,045 shares during the last quarter. Finally, Morgan Stanley increased its stake in GALAPAGOS NV/S by 10.8% in the 3rd quarter. Morgan Stanley now owns 79,319 shares of the biotechnology company’s stock valued at $8,917,000 after buying an additional 7,752 shares during the last quarter. 15.89% of the stock is currently owned by institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: Diversification Important in Investing

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report